Exact Sciences Reports Strong Q1 2025 Results

Exact Sciences Corp ( (EXAS) ) has released its Q1 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its investors.

Exact Sciences Corp., a prominent player in the cancer screening and diagnostics sector, is known for its innovative solutions like the Cologuard and Oncotype DX tests, which aim to provide clarity and early detection in cancer care.

Exact Sciences Corp. reported a robust first quarter for 2025, with a total revenue of $707 million, marking an 11% increase compared to the same period last year. The company also launched two new tests, Cologuard Plus and Oncodetect, enhancing its portfolio in cancer screening and diagnostics.

The company’s financial performance was highlighted by a 14% increase in screening revenue to $540 million and a 2% rise in precision oncology revenue to $167 million. Notably, the adjusted EBITDA saw a significant 61% increase, reaching $63 million, and the adjusted EBITDA margin improved by 280 basis points to 9%. Exact Sciences also reported a net loss of $101 million, which is an improvement from the previous year.

Strategically, Exact Sciences is on track to launch the Cancerguard EX test in the latter half of 2025 and is preparing to share pivotal study results for its colon cancer blood test. The company has also raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints, reflecting confidence in sustained growth.

Looking ahead, Exact Sciences remains focused on expanding its innovative test offerings and enhancing its market position. With a strong pipeline and strategic advancements, the company aims to continue its trajectory of growth and innovation in the cancer diagnostics field.